Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Therapeutic Pipeline Program, 2019
    CRISPRi/dCas9 Downregulation of Alpha-synuclein as a Novel Gene Therapy

    Study Rationale:
    Neurodegeneration in the brains of people with Parkinson’s may be caused by protein clumps called Lewy bodies, the pathological hallmark of the disease. Lewy bodies consist of a...

  • Improved Biomarkers and Clinical Outcome Measures, 2019
    Correlating MRI, Pathology and Cognitive Assessments toward Biomarkers of Cognitive Decline

    Study Rationale:
    Parkinson’s studies are working to identify magnetic resonance imaging (MRI) biomarkers for early diagnosis, disease severity and progression. However, attempts to explore how brain...

  • Research Grant, 2019
    Longitudinal Examination of Problems that Bother People with Parkinson’s

    Study Rationale:
    Using the Fox Insight research platform, we extracted and analyzed reports in patients’ own words about what problems bother them and how these problems affect their daily functioning...

  • Therapeutic Pipeline Program, 2019
    Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic

    Study Rationale:
    There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune...

  • Research Grant, 2019
    The Synaptic Vesicle Cycle in Parkinson’s Disease

    Study Rationale:
    Many of the proteins implicated in Parkinson’s disease appear to have a role at the nerve terminal, presumably in neurotransmitter release. However, the function of most has remained...

  • GBA Biology and Therapies, 2019
    Expression of GCase throughout Brain Vasculature for Degradation of Alpha-synuclein Aggregates

    Study Rationale:                   
    Alpha-synuclein toxicity is caused by progressive accumulation of this protein in cells. Alpha-synuclein protein aggregation is helped along by impaired lysosomes...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.